Jay R. Luly

2021

In 2021, Jay R. Luly earned a total compensation of $5.3M as President and Chief Executive Officer at Enanta Pharmaceuticals, a 2% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$518,822
Option Awards$2,283,872
Salary$693,188
Stock Awards$1,778,616
Other$19,211
Total$5,293,709

Luly received $2.3M in option awards, accounting for 43% of the total pay in 2021.

Luly also received $518.8K in non-equity incentive plan, $693.2K in salary, $1.8M in stock awards and $19.2K in other compensation.

Rankings

In 2021, Jay R. Luly's compensation ranked 2,444th out of 12,397 executives tracked by ExecPay. In other words, Luly earned more than 80.3% of executives.

ClassificationRankingPercentile
All
2,444
out of 12,397
80th
Division
Manufacturing
967
out of 5,492
82nd
Major group
Chemicals And Allied Products
368
out of 2,367
85th
Industry group
Drugs
320
out of 2,090
85th
Industry
Pharmaceutical Preparations
211
out of 1,537
86th

Pay ratio

Jay R. Luly's Pay$5,293,709
Median Employee's Pay$230,731
Pay Ratio

23

to 1

In 2021, the annual total compensation of Jay R. Luly was $5,293,709.

The annual total compensation of the median employee at Enanta Pharmaceuticals was $230,731.

The ratio of Jay R. Luly's pay to the pay of median employee was therefore 23 to one.

Source: SEC filing on January 21, 2022.

Luly's colleagues

We found five more compensation records of executives who worked with Jay R. Luly at Enanta Pharmaceuticals in 2021.

2021

Brendan Luu

Enanta Pharmaceuticals

Senior Vice President, Business Development

2021

Tara Kieffer

Enanta Pharmaceuticals

Senior Vice President, New Product Strategy & Development

2021

Yat Or

Enanta Pharmaceuticals

Chief Scientific Officer

2021

Nathaniel Gardiner

Enanta Pharmaceuticals

General Counsel

2021

Paul Mellett

Enanta Pharmaceuticals

Chief Financial Officer

News

You may also like